Tufts Medical Center, Boston, Massachusetts.
Rush University Medical Center, Chicago, Illinois.
Arthroscopy. 2020 May;36(5):1468-1475. doi: 10.1016/j.arthro.2019.12.006. Epub 2019 Dec 17.
To assess adverse effects of preoperative corticosteroid injections (CSIs) in patients with rotator cuff disease, especially before rotator cuff repair (RCR).
A systematic review of the MEDLINE database was performed according to guidelines from the Preferred Reporting Item for Systematic Reviews and Meta-Analyses for all studies reporting on adverse clinical effects of CSIs on rotator cuff tendon.
A total of 8 articles were identified that report on adverse outcomes and risks associated with corticosteroid injections in the setting of rotator cuff tendinosis. Among these included articles, a single CSI for rotator cuff tendinosis was associated with increased risk of revision rotator cuff repair (odds ratio [OR]: range 1.3 [1.1-1.7] to 2.8 [2.2-3.4]) when administered up to a year before surgery and postoperative infections (OR: 2.1 [1.5-2.7]) when administered within a month before RCR. The risk of adverse outcomes after rotator cuff repair are greatest if a CSI is administered within 6 months of surgery (OR: 1.8 [1.3-2.6]) or if ≥2 injections are given within a year of surgery (OR: range 2.1 [1.8-2.5] to 3.3 [2.7-4.0]).
Several recent clinical trials have demonstrated that CSIs are correlated with increased risk of revision surgery after RCR in a temporal and dose dependent matter. Caution should be taken when deciding to inject a patient, and this treatment should be withheld if an RCR is to be performed within the following 6 months.
IV, systematic review of Level III and IV studies.
评估术前皮质类固醇注射(CSIs)在肩袖疾病患者中的不良影响,特别是在肩袖修复(RCR)之前。
根据系统评价和荟萃分析的首选报告项目指南,对 MEDLINE 数据库进行了系统评价,以检索所有报告 CSIs 对肩袖肌腱不良临床影响的研究。
共确定了 8 篇报告肩袖肌腱病中皮质类固醇注射不良结局和风险的文章。在这些纳入的文章中,对于肩袖肌腱病,单一的 CSI 在手术前 1 年内进行与修复后肩袖修复的翻修风险增加相关(比值比 [OR]:范围为 1.3 [1.1-1.7]至 2.8 [2.2-3.4]),而在 RCR 前 1 个月内进行则与术后感染相关(OR:2.1 [1.5-2.7])。如果 CSI 在手术后 6 个月内进行(OR:1.8 [1.3-2.6])或在手术后 1 年内进行≥2 次注射(OR:范围 2.1 [1.8-2.5]至 3.3 [2.7-4.0]),则肩袖修复后的不良结局风险最大。
几项最近的临床试验表明,CSIs 与 RCR 后翻修手术的风险增加相关,且呈时间和剂量依赖性。在决定给患者注射时应谨慎,并且如果要在接下来的 6 个月内进行 RCR,则应避免这种治疗。
IV,对 III 级和 IV 级研究的系统评价。